M Vicencio - JoVE Visualize

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Filters

M Vicencio

Showing results (31-40 of 34) with videos related to

Pageof 4

Sort By:

You have reached the last page of results.This site can display upto 34 results.

Elife|December 23, 2022

Predicting progression-free survival after systemic therapy in advanced head and neck cancer: Bayesian regression and model developmentPaul R Barber, Rami Mustapha, Fabian Flores-Borja, et al.

Cell Reports|July 19, 2018

ALIX Regulates Tumor-Mediated Immunosuppression by Controlling EGFR Activity and PD-L1 PresentationJames Monypenny, Hanna Milewicz, Fabian Flores-Borja, et al.

EMBO Molecular Medicine|August 5, 2024

The MondoA-dependent TXNIP/GDF15 axis predicts oxaliplatin response in colorectal adenocarcinomasJinhai Deng, Teng Pan, Dan Wang, et al.

Cell Death & Disease|March 29, 2022

Osimertinib and anti-HER3 combination therapy engages immune dependent tumor toxicity via STING activation in transJ M Vicencio, R Evans, R Green, et al.

Pageof 4

Search research articles

Showing results (31-40 of 34) with videos related to

Sort By:

Pageof 4

You have reached the last page of results.This site can display upto 34 results.

Elife|December 23, 2022

Predicting progression-free survival after systemic therapy in advanced head and neck cancer: Bayesian regression and model developmentPaul R Barber, Rami Mustapha, Fabian Flores-Borja, et al.

Cell Reports|July 19, 2018

ALIX Regulates Tumor-Mediated Immunosuppression by Controlling EGFR Activity and PD-L1 PresentationJames Monypenny, Hanna Milewicz, Fabian Flores-Borja, et al.

EMBO Molecular Medicine|August 5, 2024

The MondoA-dependent TXNIP/GDF15 axis predicts oxaliplatin response in colorectal adenocarcinomasJinhai Deng, Teng Pan, Dan Wang, et al.

Cell Death & Disease|March 29, 2022

Osimertinib and anti-HER3 combination therapy engages immune dependent tumor toxicity via STING activation in transJ M Vicencio, R Evans, R Green, et al.

Pageof 4